Paraoxonase 1 activity as a predictor of cardiovascular disease in type 2 diabetes

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 41, Issue 5, 2010, Pages 1231-1246

  Poh, Rozaida ^a   Muniandy, Sekaran ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Cardiovascular disease; Paraoxonase 1; Type 2 diabetes

Indexed keywords

ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; LIPID;

ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; ENZYMOLOGY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALAYSIA; MALE; MIDDLE AGED; STATISTICAL MODEL;

ANALYSIS OF VARIANCE; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; FEMALE; HUMANS; LINEAR MODELS; LIPIDS; MALAYSIA; MALE; MIDDLE AGED;

EID: 79952110511     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Abbott C, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arteroscler Thromb Vasc Biol 1995; 15: 1812-8.
2. Blatter-Garin MC, Abbott C, Messmer S, et al. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J 1994; 304: 549-54.
3. Cherry N, Mackness M, Durrington P, et al. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 2002; 359: 763-4.
4. Eckerson HW, Romson J, Wyte CM, La Du BN. The human serum paraoxonase polymorphism: Identification of phenotypes by their response to salts. Am J Hum Genet 1983; 35: 214-27.
5. Ferré N, Camps J, Prats E, et al. Serum paraoxonase activity: A new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002; 48: 261-8.
6. Hashim Z, Zarina S. Assessment of paraoxonase activity and lipid peroxidation levels in diabetic and senile subjects suffering from cataract. Clin Biochem 2007; 40: 705-9.
7. Hedrick CC, Thorpe SR, Fu MX, et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000; 43: 312-20.
8. Hofer SE, Bennetts B, Chan AK, et al. Association between PON1 polymorphisms, PON activity and diabetes complications. J Diabetes Complic 2006; 20: 322-8.
9. Holland N, Furlong C, Bastaki M, et al. Paraoxonase polymorphisms, haplotypes and enzyme activity in Latino mothers and newborns. Environ Health Perspect 2006; 114: 985-91.
10. Inoue M, Ikeda Y, Suehiro T, et al. Human serum paraoxonase (PON1) concentration predicts cardiovascular disease in diabetic patients. Rome, Italy: XIV International Symposium on Atherosclerosis, 2006: 354.
11. Inoue M, Suehiro T, Ikeda Y, Kumon Y, Hashimoto K. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism 2000; 49: 1400-5.
12. James RW, Blatter GMC, Calabresi L, et al. Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. Atherosclerosis 1998; 139: 77-82.
13. Jarvik GP, Rozek LS, Brophy VH, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler Thromb Vasc Biol 2000; 20: 2441-7.
14. Jay D, Hitomi H, Griendling KK. Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med 2006; 40: 183-92.
15. Juretic D, Motejlkova A, Kunovic B, et al. Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus. Acta Pharm 2006; 56: 59-68.
16. Kosaka T, Yamaguchi M, Motomura T, Mizuno K. Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay. Clin Chim Acta 2005; 359: 156-62.
17. Lakshman MR, Gottipati CS, Narasimhan SJ, Munoz J, Marmillot P, Nylen ES. Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus. Metabolism 2006; 55: 1201-6.
18. Mackness B, Mackness M. Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. In: Reddy ST, ed. Paraoxonases in inflammation, infection and toxicology. Dordrecht: Humana Press, 2010: 143-51.
19. Mackness B, Durrington PN, Abuashia B, Boulton AJM, Mackness MI. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci 2000; 98: 355-63.
20. Mackness B, Mackness MI, Arrol S, et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentrations in non-insulin dependent diabetes mellitus. Atherosclerosis 1998; 139: 341-9.
21. Mackness B, Durrington PN, Mackness MI. The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol 2002; 13: 357-62.
22. Mastorikou M, Mackness M, Mackness B. Defective metabolism of oxidized phospholipids by HDL from people with type 2 diabetes. Diabetes 2006; 55: 3099-103.
23. Moldoveanu E, Tanaseanu C, Tanaseanu S, et al. Plasma markers of endothelial dysfunction in type 2 diabetics. Eur J Intern Med 2006; 17: 38-42.
24. Norata GD, Pirillo A, Catapano AL. Modified HDL: biological and physiopathological consequences. Nutr Metab Cardiovasc Dis 2006; 16: 371-86.
25. Parra S, Alonso-Villaverde C, Coll B, et al. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis 2006; 194: 175-81.
26. Pasqualini L, Cortese C, Marchesi S, et al. Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 2005; 183: 349-54.
27. Phuntuwate W, Suthisisang C, Koanantakul B, Mackness MI, Mackness B. Paraoxonase 1 status in the Thai population. J Hum Genet 2005; 50: 293-300.
28. Poh R, Muniandy S. Ethnic variations in paraoxonase1 polymorphism in the Malaysian population. Southeast Asian J Trop Med Public Health 2007; 38: 392-7.
29. Rahmani M, Raiszadeh F, Allahverdian S, Kiaii S, Navab M, Azizi F. Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects. Atherosclerosis 2002; 162: 381-9.
30. Richter RJ, Jampsa RL, Jarvik GP, Costa LG, Furlong CE. Determination of paraoxonase 1 status and genotypes. In: Current protocols in toxicology. New York: John Wiley & Sons, 2004; 4.12.1-4.12.19.
31. Rosenblat M, Gaidukov L, Khersonsky O, et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 2006; 281: 7657-65.
32. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: Relevance to diabetes. Atherosclerosis 2005; 187: 74e1-74e10.
33. Rosenblat M, Sapir O, Aviram M. Glucose inactivates paraoxonase 1 (PON1) and displaces it from high density lipoprotein (HDL) to a free PON1 form. In: Mackness B, Mackness M, Aviram M, Paragh G, eds. The paraoxonases: their role in disease development and xenobiotic metabolism. Los Angeles: Springer, 2007: 35-49.
34. Rozenberg O, Shiner M, Aviram M, Hayek T. Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties. Free Radic Biol Med 2008; 44: 1951-9.
35. Saeed M, Iqbal PM, Yousuf FA, et al. Interactions and associations of paraoxonase gene cluster polymorphisms with myocardial infarction in a Pakistani population. Clin Genet 2007; 71: 238-44.
36. Sarkar PD, Shivaprakash TM, Madhusudhan B. Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease. Clin Chim Acta 2006; 373: 77-81.
37. Senti M, Tomas M, Marrugat J, Elosua R. Paraoxonase-192 polymorphism modulates the nonfatal myocardial infarction risk associated with decreased HDLs. Arterioscler Thromb Vasc Biol 2001; 21: 415.
38. Sözmen B, Delen Y, Girgin FK, Sözmen EY. Catalase and paraoxonase in hypertensive type 2 diabetes mellitus: Correlation with glycemic control. Clin Biochem 1999; 32: 423-7.
39. Sutherland WHF, Walker RJ, de Jong SA, van Rij AM, Phillips V, Walker HL. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler Thromb Vasc Biol 1999; 19: 1340-7.
40. Tsuzura S, Ikeda Y, Suehiro T, et al. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism 2004; 53: 297-302.
41. van Himbergen TM, Roest M, de Graaf J, et al. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J Lipid Res 2005; 46: 445-51.
42. van Wijk J, Coll B, Cabezas MC, et al. Rosiglitazone modulates fasting and postprandial paraoxonase 1 activity in type 2 diabetic patients. Clin Exp Pharmacol Physiol 2006; 33: 1134-7.
43. Yamada A, Shoji T, Hideki T, Emoto M, Nishizawa Y. Effect of insulin resistance on serum paraoxonase activity in a nondiabetic population. Metabolism 2001; 50: 805-11.